These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36524980)

  • 1. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
    Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
    Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
    N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asciminib as a third line option in chronic myeloid leukemia.
    Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
    Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
    Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
    Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib in chronic myeloid leukemia.
    Assanto GM; Scalzulli E; Breccia M
    Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
    Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
    Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Cortes JE; Sasaki K; Kim DW; Hughes TP; Etienne G; Mauro MJ; Hochhaus A; Lang F; Heinrich MC; Breccia M; Deininger M; Goh YT; Janssen JJWM; Talpaz M; de Soria VGG; le Coutre P; DeAngelo DJ; Damon A; Cacciatore S; Polydoros F; Agrawal N; Rea D
    Leukemia; 2024 Jul; 38(7):1522-1533. PubMed ID: 38755421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
    Int J Hematol; 2024 Sep; 120(3):305-313. PubMed ID: 38888812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
    Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
    Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
    Padala S; Cortes J
    Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.